ImmunityBio’s Anktiva plus BCG demonstrates superior response durability and favourable safety profile versus approved therapies in BCG-unresponsive bladder cancer at AUA 2026
ImmunityBio announced results from two indirect treatment comparison (ITC) analyses presented at the 2026 American Urological Association (AUA) Annual Meeting evaluating nogapendekin alfa inbakicept-pmln (NAI, Anktiva) plus Bacillus Calmette–Guérin (BCG)… read more.
